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ABSTRACT
Graft versus host disease (GVHD) is a common complication in bone marrow transplant (BMT) patients. It is cha-
racterized by systemic and oral cavity alterations. Depending on the timing of lesions, GVHD is classified as acute or 
chronic. Alterations in the oral cavity are lichenoid reticular lesions, erythema, ulcerations, and xerostomia. Sporadically, 
mucocele and pyogenic granulomas can be present. Aim: To describe GVHD oral manifestations in eight allogenic BMT 
patients, and discuss GVHD and drug-immunosuppresion associated lesions diagnosis and treatment. Study design: 
For a year, we examined the oral mucosa of eight consecutive allogenic BMT patients attending the Dermatology out-
patient clinic at the Instituto Nacional de Cancerología (National Institute of Oncology) in Mexico City, looking for 
oral mucosa lesions. Results: Patients were five men and three women, ages 24.8 ± 9.7 years. Four had a BMT because of 
chronic granulocytic-, two for acute myeloblastic-, one for acute lymphoblastic- leukemia, and one for aplastic anemia. 
Three patients developed acute GVHD, with reticular oral mucosa lesions, erythema and mucositis; and all eight deve-
loped chronic GVHD, with reticular oral lesions, erythema, and ulcerations. A Patient had tongue and cheek pyogenic 
granulomas. Six reported xerostomía. Other oral lesions, associated to drug-immunosuppression, were candidiasis and 
herpes simplex. Conclusions: Patients with GVHD frequently develop oral lesions, some of which interfere with normal 
feeding; timely diagnosis and treatment are therefore essential to improve the quality of life of affected patients. We 
propose an alternative treatment for pyogenic granulomas.
Key words: Graft-versus-host disease, bone marrow transplantation, pyogenic granulomas, xerostomia, candidiasis. 
RESUMEN
La enfermedad de injerto contra huésped (EICH) es una complicación frecuente del paciente con transplante de médula 
ósea (TMO). Es un síndrome caracterizado por enfermedad sistémica y bucal. Dependiendo del tiempo de aparición de 
las lesiones, se le divide en aguda y crónica. En la cavidad bucal se manifiesta con lesiones reticulares liquenoides, eritema, 
ulceras, xerostomía, ocasionalmente mucoceles y granulomas piógenos. Objetivos: Describir las manifestaciones bucales de 
EICH en 8 pacientes con TMO alogénico, y discutir el diagnóstico y tratamiento de las lesiones de la EICH y las asociadas 
al tratamiento inmunosupresor en estos pacientes. Diseño del estudio: En el transcurso de un año se examinó la mucosa 
bucal de ocho pacientes consecutivos con TMO alogénico en la consulta externa de dermatología del Instituto Nacional 
de Cancerología de la Ciudad de México para identificar la presencia de lesiones en la mucosa bucal. Resultados: Fueron 
cinco hombres y 3 mujeres, con edades de 24.8 ± 9.7 años. Cuatro recibieron TMO por leucemia granulocitica crónica, 
dos por leucemia mieloblástica aguda, uno por leucemia linfoblástica aguda, y uno por anemia aplásica. Tres pacientes 
desarrollaron EICH aguda, con lesiones en la mucosa bucal de aspecto reticular, eritema y  mucositis, y los 8 pacientes 
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INTRODUCTION
Allogenic bone marrow transplantation (BMT), when donor 
and recipient are not immunologically identical, is used for 
malignant hematopoietic neoplasias, some solid tumors, and 
some autoimmune diseases (1,2). Amongst the most fre-
quent complications of this treatment is Graft-versus-Host 
Disease (GVHD) (1,2). GVHD is the outcome of donor’s T-
lymphocytes reacting against recipient’s antigens, depending 
on type and number of histocompatibility mismatchings 
(1,2). GVHD occurs in 50 to 80% of patients receiving an 
allogenic BMT, and is a cause of high long-term morbidity 
and mortality in these patients (1-3). GVHD is characterized 
by dermatological, gastrointestinal, and hepatic lesions. The 
acute form (aGVHD), with lesions appearing during the 
first 100 days after BMT, is a high-mortality complication 
(1-4). Chronic form (cGVHD), developed more than 100 
days after BMT, is an autoimmune disease with dermatosis, 
liver dysfunction, pulmonary fibrosis, alterations in oral 
and gastrointestinal mucosa, and decreased salivary and 
lachrymal flow (1-3). Some oral lesions are included in 
the clinical manifestations of GVHD, and their presence 
is highly predictive of  this complication. These are very 
symptomatic, persistent lesions, occurring in 30 to 80% of 
BMT patients (3-6). 
AIM
To describe oral manifestations of GVHD identified in eight 
BMT patients, and discuss diagnostic criteria and treatment 
of these lesions, as well as those oral lesions associated to 
immunosuppressive treatment.
PATIENTS AND METHODS
We describe the oral manifestations of acute and chronic 
GVHD, identified in eight ambulatory patients with alloge-
nic bone marrow transplant examined at the Dermatology 
Service of the Instituto Nacional de Cancerología (National 
Institute of Oncology) in Mexico City.  Dermatological and 
oral mucosa examinations were performed by a dermato-
logy specialist and a specialist in oral pathology. Primary 
disease diagnosis, evolution time and treatment, as well as 
BMT protocol studies results and post BMT management 
information was obtained from clinical records. Manage-
ment of primary disease went along established protocols 
for allogenic BMT: chemotherapy -depending on primary 
disease- with methotrexate, cyclophosphamide, busulfan or 
etoposide, and total body irradiation (1,7). The criteria used 
for clinical diagnosis of oral lesions were those by Kolbinson 
et al. (6) for oral manifestations associated to BMT. 
RESULTS
Five men and three women were studied, ages 24.8 ± 9.7 
(14-43) years. Seven patients had a previous diagnosis of 
leukemia; four chronic granulocytic, two acute myeloblastic, 
and one acute lymphoblastic, and one had aplastic anemia. 
One patient (case 4) received two allogenic BMTs in a one-
year period. Table 1 presents GVHD classification and the 
characteristics of the patients.  
Three patients (cases 2,6,7) developed aGVHD with severe 
mucocutaneous lesions 12 to 45 days after BMT. Oral le-
sions were white, small papules with a reticular character in 
non-keratinized mucosa. Six patients (cases 1,2,3,4,5,7) had 
mucositis, probably associated to chemotherapy. Five (cases 
1,2,4,5,7) developed pseudomembranous candidiasis, one 
of them (case 2) extended to esophagus, and three (cases 
1,4,7) had intra-oral herpes simplex. The oral lesions co-
existed with cutaneous hyper pigmented lesions, xeroderma, 
generalized maculopapular eruptions, and erythematous 
maculae. Two cases developed gastrointestinal and liver 
function alterations.
All eight patients developed cGVHD, with cutaneous and 
oral lesions appearing between days 117 and 507 after BMT. 
Chronic GVHD diagnosis was based on clinical manifes-
tations and their timing, and confirmed by skin- and, in 
four patients, oral mucosa biopsies. The oral lesions were 
reticular-looking, raised striae on vestibular mucosa. Three 
patients had them also on hard palate and tongue. Seven 
patients had ulcers with diffuse, erythematous borders on 
buccal mucosa. Case 8, a man with a BMT because of 
aplastic anemia, developed three ulcerated firm mass on 
tongue dorsum and buccal mucosa, which lasted more than 
two months (Fig. 1). An incisional biopsy revealed pyoge-
nic granulomas (PG). All patients informed severe pain on 
oral mucosa, six xerostomia -diagnosed when the mucosa 
was clearly dry and/or the patient reported dry mouth with 
difficult eating or talking; salivary flow was not measured. 
Four biopsies of lip mucosa revealed hyperparakeratosis, 
basal cell layer degeneration, subepithelial lymphocytic in-
filtration, lamina propria mucosa fibrosis, and sub mucous 
salivary glands atrophy (Fig. 2).  Three patients (cases 1,2,4) 
developed intraoral herpes simplex. Four (1,3,4,5) develo-
ped herpes zoster. Other alterations were conjunctivitis, 
xerophtalmia, and blepharitis. 
desarrollaron EICH crónica, con lesiones reticulares, eritema, y ulceras. Un paciente presentó granulomas piógenos en 
lengua y carrillos. Seis informaron xerostomía. Otras lesiones bucales, asociadas a inmunosupresión  medicamentosa, 
fueron candidosis y herpes simple bucal. Conclusiones: Los pacientes con EICH frecuentemente desarrollan lesiones 
bucales, algunas de ellas impiden una alimentación normal, por lo que es fundamental su diagnóstico y tratamiento 
oportunos para  mejorar la calidad de vida de los pacientes afectados. Se propone una forma alternativa de tratamiento 
para los granulomas piógenos.
Palabras clave: Enfermedad injerto contra huésped, transplante de médula ósea,  granulomas piógenos, xerostomía, can-
didosis.
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Six cases had diarrhea and vomiting. Case 2 developed 
pulmonary tuberculosis and varicella, and case 6 presented 
severe liver complications; both died, at 181 (case 6) and 
1345 (case 2) days after BMT. 
Prescribed treatments for oral lesions were: diphenhydrami-
ne with kaolin and pectin or clobetasol gargles, topic fluo-
cinonide, oral prednisone (20 to 50 mg/day) or thalidomide 
(50 to 200 mg/day) for lichenoid lesions, and nystatin gargles 
or oral fluconazole (100 to 200 mg/day) for mycotic lesions. 
In the patient with pyogenic granulomas surgical treatment 
was avoided because of neutropenia, and lesions were in-
Fig. 1. Ulcerated, firm lobulated masses on the dor-
sum of the tongue and vestibular mucosa, diagnosed 
as pyogenic granulomas associated to reticular and 
ulcerated lesions. 
Fig. 2. Epithelium with hyperparakeratosis, basal 
cell layer degeneration, moderate chronic subepi-
thelial inflammatory infiltrate, and fibrosis of the 
lamina propria. 
Fig. 3. Remission of the lesion, after intralesional corti-
costeroid infiltration. 
Case  
No Gender Age Diagnosis 









No   1 M 34 LGC1 117 -- G11/ 1V 1773 WithoutGVHD
No   2 M 20 LMA2 12 GI/1V G111/IV 1345 Died 
No   3 F 43 LGC 507 -- G11/ 1V 2555 Stable cGVHD
No   4 M 14 LGC 461 --- G11/1V 2765 Stable cGVHD
No   5 F 27 LGC 156 --- G11/1V 2611 WithoutGVHD
No   6 M 23 LGC 28 G11/IV G1/1V 181 Died 
No   7 F 16 LAL3 45 G1/1V G1/1V 1765 Stable cGVHD
No   8 M 21 AA4 120 --- G11/111 750 Stable cGVHD
Table 1. Clinical characteristics of the eight BMT patients and acute and chronic GVHD 
1 Chronic granulocytic leukemia,  2 acute myeloblastic leukemia, 3 acute lymphoblastic leukemia, 4 aplastic anemia, 5ref 
(1).
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filtrated twice a month with 5 mg triamcinolone, obtaining 
resolution after the third application (Fig. 3).
DISCUSSION
Oral mucosa was seriously affected both in acute and 
chronic forms of GVHD, by several progressive, weakening 
lesions. GVHD is an autoimmune alteration, where donor’s 
T-lymphocytes play a key role in immunological assault on 
host tissues. Acute and chronic forms differing on clinical 
and immunological grounds (3,8), Acute GVHD represents 
an immunological alteration with a mostly TH1- type cyto-
kine production pattern and skin, liver, and gastrointestinal 
tissue lesions caused by T-killer cells (1-3), while the chronic 
form (cGVHD) is a rather specific immuno-histocompati-
bility phenomenon with an autoimmune disease behaviour, 
a predominating TH2-type cytokine production pattern, 
and systemic manifestations (3,8). In GVHD, donor’s T 
lymphocytes attack recipient tissues, particularly epithelia, 
resulting in apoptosis (2,9). T-lymphocytes release within 
assaulted cells protease granules known as granzymes, or 
they activate plasma membrane receptors such as TRAIL, 
from the TNF-α family. Both mechanisms activate cell’s 
apoptotic machinery (10), even if  T-lymphocytes are the 
main immune response effector cells, other cellular types 
have been identified in experimental models during the 
immunological response at the damaged site and in oral 
mucosa, such as plasma cells, macrophages, mastocytes, 
and Langerhans dendritic cells (10,11).  
Identified risk factors for GVHD are increasing HLA dis-
parity between recipient and donor (3), age -the syndrome 
being 80% more frequent in patients over 50 years- (1-3), 
donor type (unrelated), lacking of prophylactic acyclovir 
treatment for herpes virus infection or total body irradia-
tion, and type of chemotherapy before BMT (1-3). Being 
of  African-American origin has also been considered a 
possible risk factor (12).
Oral lesions are common sequelae in acute and chronic 
GVHD. Reported prevalence are 33 to 50% for aGVHD 
(4), and 60 to 80% for cGVHD (4,5). Three patients in this 
study developed raised interlacing white striae and diffuse 
oral mucosa ulcerations, xerostomia and diarrhea, matching 
the description of aGVHD. The oral lesions appear between 
days 21 and 43 after BMT (5); and whitish 1-mm papules with 
a reticular lichenoid pattern, oral mucosa exfoliation, and 
painful ulcerations have been described, that resolve before 60 
days (4,6). A distinction must be made between oral lesions 
induced by aGVHD and those associated to pre-transplant 
chemotherapy. Chemotherapy-induced ulcerative mucositis 
presents as mucosal erythema and atrophy, pain, and xe-
rostomia, and appear 7 to 14 days after treatment in 76.3% 
of the cases (13-15). Chemotherapy-associated mucositis is 
caused by drug cytotoxicity inhibiting epithelial cell division 
and maturation, resulting in atrophy and ulceration (15,16). 
The associated neutropenia predisposes, on the other hand, 
to opportunistic infections such as candidiasis (6,15,16). 
Irradiation of head and neck induce irreversible changes in 
major salivary glands, resulting in xerostomia (16).
Chronic GVHD can occur either as a non resolving acute 
form, which represents a bad prognosis, or de novo, more 
than a hundred days after BMT (2,3,8). It can be a limited 
disease affecting skin, oral cavity or liver, or a dissemina-
ted one, affecting two or more organs, i.e. skin and/or oral 
mucosa lesions combined with hepatic, ocular alterations, 
sicca syndrome, pulmonary and/or central nervous system 
disease (3-5). This is a high-mortality, systemic, progressive 
condition (3); two of the patients from this report died (cases 
2 and 6), one from pulmonary tuberculosis and the other 
from liver disease.
An up to 80% prevalence of oral lesions has been reported 
in cGVHD (3-5,17-19). Reported lesions or oral manifes-
tations are mucosal atrophy, mucositis, lichenoid lesions, 
ulcerations, severe oral pain, xerostomia, dysphagia and, 
occasionally, blister-type lesions resembling pemphigus 
(4,5,17-20). The most representative lesions are the liche-
noid ones, both in pediatric (17,21) and adult (3-5,18-20) 
patients. Treister et al. (21) reported a 45% prevalence of 
oral lesions in children with cGVHD, erythema (42%) and 
reticular lesions (36%) being the most frequent ones. They 
also reported atrophic glossitis, superficial mucocele, ve-
rruciform xanthoma, and mucosal fibrosis, which limited 
mouth opening. Reticular lesions are generally symmetrica-
lly distributed in vestibular, labial, gum, and tongue mucosae 
(3-5,19,20). Differential diagnoses includes lichen planus 
(3,5,18-20), erythema multiforme, lupus erythematous, pem-
phigus (5,19), scleroderma-systemic sclerosis (5,18-20), and 
chemotherapy-associated lesions (6,16). Even though lichen 
planus and the cGVHD oral lesions resemble each other, 
Hasséus et al. (22) reported different prevalence of cells with 
inflammatory response membrane markers between both 
diseases, with a larger amount of CD1, CD86, CD4, CD8, 
and CD25 positive immunocompetent cells in lichen planus 
as compared to cGVHD, implying a different regulation of 
the inflammatory response both conditions.
Suggested local measures for oral lesions treatment are 
medications such as diphenhydramine with kaolin and 
pectin or magnesium sulfate mouth washes, which reduce 
pain (16), topical steroids or azathioprine (23), budesonide 
gargles (24) and ultraviolet irradiation (25) or systemic 
medication such as prednisone, Cyclosporin-A (3,5), aza-
thioprine (2,3), thalidomide (2,3), mophetyl mycophenolate, 
and tacrolimus (3). 
Definitive cGVHD diagnosis depends on disease duration 
and evidence for end organ damage, and is confirmed by 
skin, oral mucosa –including salivary glands– or digestive 
tract biopsy. Oral mucosa biopsy shows epithelium hyperpa-
rakeratosis or atrophy, basal stratum hydropic degeneration, 
subepithelial clefting which occasionally form ampulae; on 
stratum spinosum isolated necrotic keratinocytes with pyc-
notic nuclei, intracellular epithelial edema, and apoptotic 
bodies. On connective tissue, slight or diffuse sub-epithelial 
lymphocyte infiltrate and fibrosis of the lamina propria (26). 
On lip and submaxillary salivary glands, apoptotic cells, 
lymphocyte infiltration, periductal fibrosis and conduct 
dilatation between acini (19,20,26,27). These histological 
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changes are usually associated to hyposalivation and xe-
rostomia (20,27). Fujiwara et al. (11) and Soares et al. (26) 
identified by immunohistochemistry a high prevalence of 
positivity to CD68, CD45, and CD8 markers in biopsies 
of labial mucosa and minor salivary glands, and concluded 
that macrophages and T cells play a key role on disease 
pathogenesis. Histologically, GVHD must be distinguis-
hed from lichen planus, lupus erythematous and Sjögren’s 
syndrome (19,20).
Xerostomia is a frequent symptom in the GVHD patient 
(19,20,28). It causes mastication, swallowing and spea-
king difficulties, and predisposes to Candida infections 
(19,28), angular cheilitis (13), and rampant caries  (17). 
Among causes for xerostomia are included head and neck 
irradiation, drugs used for malignant disease and GVHD 
treatment (16,19,20,27), decreased salivary flow, saliva 
chemical composition changes with increased sodium, 
magnesium, total proteins, epithelial growth factor, IgG 
and IgA concentrations (27,29). Six patients from this study 
informed dry mouth, diagnosed as xerostomia on the basis 
of symptoms, the finding of viscous saliva, and a dry oral 
mucosa. The clinical manifestations are similar to Sjörgren’s 
syndrome (SS), but there are some clinical and histological 
differences between these diseases (20,27,28); spontaneous 
pain and inflammation of the parotid glands are frequent 
in SS, but are not found in GVHD (29,30). Xerostomia 
management suggestions are sugar-free gum chewing, use 
of gels, toothpastes, saliva substitutes (28), and pilocarpine 
administration (29,31). 
Pyogenic granuloma is another oral lesion occasionally 
reported in association with GVHD (32,33), It is a reactive-
type entity with granulation tissue proliferation. Though 
it has not been described as a BMT complication proper, 
several reports in the literature do associate it with GVHD. 
It is described as a firm mass on buccal mucosa or ventral 
or dorsal tongue, irregular in shape, intensely red, with 
sessile or pedunculated base, frequently lobulated, genera-
lly ulcerated, single or multiple (32,33). In this study, one 
patient with a history of aplastic anemia presented these 
lesions on oral mucosa and tongue; the biopsy confirmed 
pyogenic granulomas (PG). The histopathological study 
shows hyperplastic granulation tissue with acute and chro-
nic inflammatory infiltrate and variable fibrosis (32,33). 
Etiology of  PG in GVHD is still unknown; it has been 
considered probably associated to Cyclosporine-A use, 
because of its known proliferative effect on oral mucosa 
fibroblasts (34). Differential diagnosis requires a biopsy, 
because drug immunosuppression is a risk factor for viral 
lymphoproliferative disease, which presents itself  with swe-
llings or ulcerations in the oral cavity (35). PGs are normally 
excised. In the informed case, because of neutropenia, and 
based on literature reports on treatment for other reactive 
lesions, a less invasive therapy was used, with intra-lesional 
infiltration of a corticosteroid (36). The mechanisms by 
which reactive lesions respond to corticosteroid infiltration 
are not yet known; a hypothesis stating it inhibits lysosomal 
proteins release into the extracellular environment (36). The 
favorable evolution reported in the literature for similar 
lesions, and the low complications rate from this treatment 
led us to choose this procedure as a treatment alternative 
for pyogenic granulomas in immunocompromised or throm-
bocytopenic patients, to avoid bleeding and lower the risk 
of added bacterial infection.
In this study, no superficial mucoceles were found; their 
presence, however has been reported in children and adults 
with cGVHD (17,21,37), developing on labial, oral, and soft 
palate mucosa, occasionally in association with reticular 
lesions. These are small sialomucin collecting vesicles in 
the subepithelial connective tissue (17,21,37), their etiology 
still unknown. García et al. (37) proposed they are probably 
a manifestation of cGVHD in the glands, attributable to 
obstruction or rupture of the intraepithelial portion of the 
salivary conducts by increased ductal pressure -by mucous 
secretion- in salivary glands. 
On the other hand, excessive drug-immunosuppression, 
radiotherapy, and chemotherapy used for primary disease 
treatment, predispose to opportunistic infections (15,16). 
The most frequent infections in BMT are those by Candida. 
(6,16). The risk for Candida infection increases as a result of 
decreased IgA concentration in saliva associated to xerosto-
mia and neutropenia (16,28,38). Epstein et al. (38) reported 
a 31% prevalence for oral colonization by Candida in BMT 
patients, and 56% of those carriers had clinical candidiasis. 
Acute pseudomembranous candidiasis is the most frequent 
presentation in patients with compromised salivary glands 
(16,19), but all clinical forms: erythematous, pseudomem-
branous, hyperplastic, and angular cheilitis can be seen at 
some point in the course of the disease. Prophylaxis with 
fluconazole and chlorhexidrine mouth washes reduces 
Candida colonization prevalence, lowering the risk for sys-
temic dissemination (16,39). Topical treatment is done with 
nystatin suspension or cream, or clortrimazole lozenges dis-
solved in the oral cavity, and chlorhexidrine mouth washes. 
First choice drugs for systemic treatment are fluconazole, 
ketoconazole, or itraconazole (14,38,39).
Another cause of oral morbidity in BMT patients is reactiva-
tion of virus from the herpes simplex (HS) family (6,16), with 
a reported incidence of 50-90% (40). It has been proposed that 
reactivation of latent virus in a sensorial ganglion is associated 
to decreased –through several mechanisms- local defenses, for 
instance through depletion of Langerhans cells or deterioration 
of their competence for antigen presentation and of immediate 
or late immunity to the virus; effects in which local production 
of prostaglandins seem to play a role (41). Viral reactivation is 
thus associated to recurrence of the lesions (41). Clinical pre-
sentation is one of severe, extensive, painful, slowly resolving 
ulcerated lesions, some times preceded by blisters occurring in 
gum, palate, and tongue, frequently confounded with mucositis 
or cGVHD lesions (16,19). Prognosis of the BMT patient has 
been considered pessimistic with recurring HS lesions and 
platelet counts below 100,000/mm3 (42). Sporadically, other 
lesions associated to the herpes virus family have been reported 
in BMT patients, such as extensive, long-lasting ulcerations on 
the lateral borders of the tongue, associated to cytomegalovirus 
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(43) and hairy leukoplakia on the lateral border of the tongue, 
associated to Epstein-Barr virus (EBV) (44). EBV is known for 
its association with lymphoproliferative disease and immuno-
suppression-induced lymphomas. Raut et al. (35) presented a 
case of gum non-Hodgkin lymphoma in a BMT patient. It has 
been demonstrated that prophylaxis with acyclovir, valacyclovir 
or valgancyclovir result in a lower incidence of lesions due to 
herpes simplex and cytomegalovirus (16,45).
Stomatologist involvement is pertinent in these patients. 
Before and after BMT, preventive measures must be taken 
to avoid opportunistic and bacterial infections, including 
dental infectious foci treatment, to avoid dissemination 
(46).  It is suggested that dental care, with required surgical 
procedures as caries elimination, exodontias, periodontal 
treatment and topical application of fluorinated gel (46), 
be started 2-3 weeks before chemotherapy.  It is also sug-
gested that, prophylactic drugs be used before BMT, such 
as acyclovir, fluconazole, trimethoprim/sulfamethoxazole 
and chlorhexidrine (39,45), against opportunistic microbes 
and, after BMT, artificial saliva or pilocarpine (28,31), as 
well as  taking the necessary  therapeutic measures to treat 
the multiple oral alterations in these patients. 
CONCLUSIONS 
GVHD is a frequent complication of BMT, with a high mor-
bidity attributable to oral lesions that must be differentiated 
from other infectious and autoimmune conditions occurring 
in the oral mucosa. Interaction between hemato-oncology 
and stomatology is needed for timely diagnosis and treat-
ment of  oral complications, and preventive intervention 
programs. Intralesional corticosteroid Infiltration for pyo-
genic granulomas is proposed as an alternative treatment 
in the immunosuppressed patient.
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